pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BeOne Medicines Ltd. ($ONC) · news · pharmadog
← back to BeOne Medicines Ltd.
News mentioning $ONC
20
stories
17d
DPHARM: How to address the clinical trial enrollment crisis?
fiercebiotech
24d
Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake'
biospace
Sep 2, 26
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
biospace
Sep 1, 26
Mid-cap biotechs join Trump’s latest round of drug pricing deals
biopharma dive
Sep 1, 26
9 midsize drugmakers climb aboard Trump’s MFN train
biospace
Aug 28, 26
Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact
fiercebiotech
Aug 26, 26
Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
biospace
Aug 25, 26
New Jazz cancer drug approval could drive blockbuster sales
biopharma dive
Aug 6, 26
Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
fiercebiotech
Jul 27, 26
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
Jul 23, 26
BeOne commits $300M to US manufacturing expansion, creating 120 new jobs
biospace
Jul 21, 26
Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assets
fiercebiotech
Jun 30, 26
Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
biopharma dive
Jun 30, 26
BeOne’s Brukinsa succeeds in frontline mantle cell lymphoma study
endpoints
May 15, 26
Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
biopharma dive
May 14, 26
BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta
endpoints
May 6, 26
BeOne culls five cancer programs and an autoimmune Phase 2
endpoints
Apr 28, 26
BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF
endpoints
Apr 28, 26
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
biopharma dive
Dec 22, 25
Fierce Biotech Fundraising Tracker '26: TriGemX tacks on $94M; AnaCardio adds $71M
fiercebiotech
